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Abstract: Menopause is a natural phase of life and happens in every woman who reaches a certain age. This condition 
has many problems, such as endometrial atrophy, which can cause abnormal bleeding. Sauropus 
androgynus, known as Katu Leaf, has isoflavones compound and acts as an estrogen-like agent or 
phytoestrogen. Isoflavone can induce cell proliferation activity in increasing endometrial thickness and 
uterine weight. This study was aimed to find how the is flavone compound in Sauropus androgynus can 
increase the uterine weight in menopausal mice as an animal model. Twenty female mice aged two months 
and one week were given VCD (4-Vinyl cyclohexane dioxide) to induce the atresia acceleration of ovarian 
follicles, then treated with Katu Leaf extract of 0, 15 and 30mg/kgBW over four weeks. The uterine weights 
were measured and analyzed with One Way Analysis of Variances (Anova) and further tested with Least 
Significance Difference in 95% confidence interval. The result showed a difference between control and 
treatments group (p<0.05) with 30mg/kgBW as highest dosage, which increase uterine weight as 112.80 
+8.86mg), but this is not higher than normal (116.36+6.83mg). This study suggests that Katu Leaf extract 
has an isoflavone compound which can increase uterine weight in menopausal mice. 
1 INTRODUCTION 
The revolution in healthcare, education, knowledge 
and income levels has led to higher life expectancy. 
The increase in life expectancy also causes the 
number of women who enter the menopausal phase 
to become higher. Menopause at 45 to 50 years old 
is caused by decrease of ovary ability, resulting  in 
the decline of estrogen hormone levels (Gold, 2011). 
The estrogen and others of the nuclear receptor 
(NRs) superfamily play roles as nuclear transport 
proteins, cell cycle and transcription factors. The 
steroid hormones act by binding to nuclear receptors 
as ligand-inducible transcription factors. Estrogen 
has many functions in growth, differentiation and 
other non-reproductive  metabolism functions. 
Estradiol, a kind of estrogen, gives a female 
characteristics, regulates reproductive cycles, 
pregnancy, skin, immunity, protects the 
cardiovascular system, bone mass and brain system 
(Sunita and Pattanayak, 2011). 
Decreased ovarian function in menopause causes 
hypoestrogenism. Estrogen deficiency during 
menopause can lead to risk for many health 
problems, such as atrophy of the female genital tract, 
hot flushes, sleeping disorders, vaginal dryness, joint 
pain, mood swings, reduced bone density, 
cardiovascular disease and more (Cavadas et al., 
2010). The American College of Obstetricians and 
Gynecologists stated that the decline of estrogen 
levels in menopause causes reduction of 
endometrium thickness or endometrial atrophy. This 
condition may cause abnormal bleeding as one of 
the health problems in menopause. 
The classical therapy of reducing vasomotor 
symptoms, especially hot flushes and urogenital 
atrophy, in menopausal women is with hormone 
replacement therapy (HRT). However, recent study 
shows that the use of HRT is related with increasing 
breast and endometrial cancer risk; thus, researchers 
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 have to look for other therapeutic alternatives 
(Rymer, Wilson and Ballard, 2003). 
In recent few years, isoflavones has become 
known as an alternative to HRT because they are 
reported safer, to be an estrogen agonist and have 
weak activity. This action is termed phytoestrogen, 
which is a definition applied to any plant substance 
or metabolite that induces biological responses in 
vertebrates and can modulate the actions of 
endogenous estrogens, usually with the binding to 
estrogen receptors (ERs) (Molla, 2001; Sunita, 
2010). Isoflavone is the most studied of 
phytotherapeutic agents, found mostly in soy with its 
main compounds being  genistein, daidzein, 
biochanin A and formononetin (Setchell, 2001). 
Phytoestrogen has two hydroxyl (OH) within 11.0 to 
11.5A0 in its core, exactly the same as estrogens. 
Distance 11A0 and the OH group are the basic 
structure of a substrate in order to have estrogenic 
effects (Boker et al., 2002; Zand, 2000). 
Katu Leaf (Sauropus androgynus (L.) Merr.) has 
a potential as a phytoestrogen according to the 
research results on Katu Leaf content by Ekawati 
(2009) and Miean (2000), who found that Katu Leaf 
has flavonoid compounds, flavone, flavonol, and 
isoflavones and also has a quercetin. Moreover, 
Santoso (2010) suggests that this leaf contains the 
active Androstan-17-one,3,-ethyl-3-hydroxy-5alpha 
which has precursor function or intermediate step in 
steroid hormones synthesis. Boker et al., (2002) 
reported that the isoflavones and quercetinas 
phytoestrogens have structural similarity to estradiol 
in its rings and cause estrogenic activity and are able 
to bind to estrogen receptors. 
The use of phytoestrogens, especially isoflavone 
and quercetin agents, for menopausal therapy 
alternatives has been widely studied. Burton (2002) 
said that use of isoflavones is a safer therapy which 
increases endometrial thickness and also cancer 
preventative agents. Goodman, et al. (1997) found 
that, although there was a negative correlation 
between dietary fiber intake and the risk of 
endometrial cancer, there was also an inverse 
correlation between isoflavones intake and the risk 
of endometrial cancer. In addition, Bandera et 
al.(2009) said that there is a reduction in endometrial 
cancer risk with quercetin and isoflavone 
consumption. 
Many studies, especially with animal models, 
show the action of phytoestrogen intake in uterus or 
other female genital tracts. However, the action of 
Sauropus androgynus is known to have isoflavones 
and quercetin compound in menopause. The 
objective of the present study was to investigate 
whether the actions of Sauropus androgynus 
compound can increase the uterine weight in 
menopausal mice as an animal model. 
2 METHODS 
2.1 Experimental Design and Sampling 
This study was an experimental study using 
completely randomized design with five  
replications. Menopausal condition was done by 
giving VCD (4-vinyl cyclohexane dioxide) then in 
group treatment was given with Katu Leaf Extract 
(KLE) to know the effect. The study groups 
consisted of K- (control group, normal), K+ 
(VCD+KLE 0mg/kgBW), P1 (VCD+KLE 
15mg/kgBW), P2 (VCD+KLE 30mg/kgBW). 
Tools and materials used included  female mice, 
cages, food, Katu leaf, water, VCD (4-vinyl 
cyclohexane dioxide), sesame oil, Giemsa staining, 
freeze dryer, chloroform, NaCl 0.9% and analytical 
balance. 
2.2 Katu Leaf Extract 
Sterilized and shade air-dried Sauropus androgynus 
leaves were extracted with water extract methods 
and preserved with freeze-drying according to  Popp 
et al. (1996) in the Chemistry Laboratory of 
Muhammadiyah University of Malang.  
Powdered Katu leaves were soaked in boiling 
distilled water. Filtrate were extracted a second time 
with  additional boiling distilled water. The 
combined filtrate was then freeze-dried, and the 
sticky precipitate was stored at 4°C. Aliquot of 
extract residue were weighed and suspended in de-
ionized distilled water to a final concentration before 
use. 
2.3 Animals 
Twenty  female balb/c mice aged two months and 
one  week, 25-30gm, were obtained from the Animal 
Biosystematic Laboratory of State University of 
Malang, housed in plastic cages with wooden chip 
bed, given food and water ad libitum, and exposed to 
a light-dark cycle of 12 hours as its cyrcadian 
rhythm following Eckel-Mahan and Sassone-Corsi 
(2015). 
Samples treatment was performed in  laboratory 
under controlled and constant condition. Samples 
used in this study were observed to know if there 
was a change in body weight during the study. 
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 2.4 Animal Models of Menopause 
Menopausal condition was done by giving VCD (4-
vinyl cyclohexane dioxide) according to the research 
conducted by Kempen, Milner and Waters (2011) 
which states the administration of low dosage of 
160mg/KgBW for 10 days in 14 days (five  times a 
week within 14 days) intraperitoneally. 
2.5 Estrous Cycle Observation 
Estrous cycle was determined by observing the 
results of the vaginal smear and Giemsa staining by 
Marcondes, Bianchi and Tanno, (2002). The 
constituent phases determination of the estrous cycle 
and long-cycle was conducted by comparing 
nucleated epithelial cells, gore epithelial cells 
(cornification), leucocytes, mucus and the vaginal 
smear results. 
The normal estrous cycle length in mice is 
approximately 3-4 days, the cycle change indicated 
the beginning of menopause. Compared with human, 
Harlow and Paramsothy (2011) said that menopausal 
transition begins with variability in menstrual cycle 
length. 
2.6 Data Collection 
Animals were terminated on diestrus phase then 
uterine samples were isolated and weighed using 
analytical balance, measured in milligrams. 
2.7 Statistical Analysis 
Collected data were tested with Shapiro-Wilk 
normality test and Lavene homogenity test. If the 
results were normal and homogeneous (P>0.05) then 
it was continued with 5% one way Anova analysis. 
If there was a significant change, it was further 
tested with LSD (Least Significance Difference) 5%. 
3 RESULTS 
The results obtained from the current study and 
presented in Table 1 revealed that the group with 
Katu Leaf extract showed significant (p<0.05) 
increase of uterine weight (91.82 + 10.43mg versus 
107.58 + 10.40mg and 112.80 + 8.86). The study 
groups  treated with Katu Leaf extract intake (P1, 
P2) showed higher weight of uterine than those not 
treated. Increased uterine weight in mice may be 
caused by increase of endometrial thickness. 
Table 1: Uterine weight in mice treated with different 
doses of Katu Leaf extract. 
Study Groups Uterine weight 
(mg) 
P 
K+ (VCD + KLE 0 mg/kgBW) 
P1 (VCD + KLE 15 mg/kgBW) 
P2 (VCD + KLE 30 mg/kgBW) 
K- (normal group)
91.82 + 10.43 
107.58 + 10.40 
112.80 + 8.86 
116.36 + 6.83 
0.004*
*p <0.05 indicates that there is significant difference 
between treatment and control groups 
 
Increased uterine weight is directly proportional 
with the dose of Katu Leaf extract, shown in Figure 
1. The highest uterine weight is in normal group, 
without any treatments. 
The average of uterine weight is affected by Katu 
Leaf treatment known from correlation test between 
uterine weight (x) and body weight (y). Pearson test 
shows that there is no relationship between uterine 
weight and body weight (p>0.05). The mice body 
weight may be changed by decreasing levels of 
estrogen, but, in this study, we found that the change 
of the uterine weight was not affected by the mice 
body weight. 
 
Figure 1: Increase of mice uterine weight treated with 
different doses of Katu Leaf extract. 
4 DISCUSSION 
Estrogen action in the body is by binding with 
estrogen receptors (ER), ER-α or ER-β, which have 
its own function. Recent studies show that the uterus 
has two receptors with different function. ERα is for 
maturation, paracrine and autocrine mitotic 
activation and function of uterine tissues, while ERβ 
is expressed in the uterus for genital development, 
including regulating the  development of stromal, 
myometrial and uterine glands (Dupont et al., 2000). 
Development of the genital tract is then shown in the 
uterine weight. 
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 From Table 1, it may be found that miceuterine 
weight is higher by giving Katu Leaf extract. 
Previous study by Helmy (2014) shows that the 
phytoestrogen intake can increase the endometrial 
thickness and then the uterine weight. This action is 
modulated  by binding of the isoflavone and 
estrogen receptors. The type of estrogen receptor is 
ERβ, known from immunostaining, which shows 
that it is more expressed and isoflavone is known as 
preferential affinity with ERβ. The complex binding 
of ligand and receptor induces the expression of 
estrogen-responsive genes, which ultimately results 
in increased uterine mass. 
In this study, menopause mice condition was 
with 4-Vinyl cyclohexane dioxide (VCD) induction. 
VCD causes accelerated ovarian follicle atresia 
through the increased apoptosis protein and may 
cause declined ovarian ability to produce estrogen 
and boost uterine growth (Hu et al., 2001). Reduced 
human blood estrogen concentration causes reduced 
thickness of the endometrium, then uterine glands 
are not able to make secretion and results in loss of 
uterine weight. 
Moggs et al. (2004) said that animal uterus with 
ovary disorder is very sensitive to the effect of 
estrogenic compound. Giving estrogen-like 
compounds causes hyperemi and water imbibitions 
into the uterus, with increased regular metabolism 
degree as a result of increased use of oxygen, the 
increase in the degree of phosphorus use, the 
increased glycolicis degree and the increased 
amount of DNA, RNA and proteins. 
Cooke et al. (1998) also explain about the 
mechanism of this process, wherein a phytoestrogen 
compound will bind with hormone receptors on 
target cells, thus changing hormone receptor 
conformation. This conformation change leads to an 
active phytoestrogen receptor, thus it will be able to 
perform binding site on the DNA chain, specifically 
on the acceptor side. The interaction between 
phytoestrogen receptor and the DNA acceptor side 
causes the increased gene expression. This gene 
expression is then catalyzed by an RNA polymerase 
enzyme, which may lead to  increased mRNA. 
Moreover, tRNA synthesis will also increase and 
cell material synthesis becomes higher, which may 
support cell proliferation activity. 
Although there was an increase in uterine weight 
in the treatment groups, as shown in Figure 1, this 
was not higher than the control group. This result 
indicates that phytoestrogen intake is safe and does 
not increase endometrial risk as the proliferation 
activity is in normal levels. But, as  is known there 
are still pros and cons regarding the use of 
phytoestrogens for menopausal therapy is, mostly 
concerning the breast and cancer risk, although 
many recent studies have concluded that 
phytoestrogens can even reduce carcinogenesis risk 
(Patisaul and Jefferson, 2010).The study by Ferraz 
Carbonel et al. (2011) concluded  that isoflavones 
consumption in normal dose is of benefit for the 
body, including have an uteotropic effect, but that 
too high a dose of isoflavones can promote 
endometrial squamous metaplasia. In this study, we 
found that the dose we use is safe. However, it 
should be further investigated concerning a high 
dose of Katu Leaf and how to determine the correct 
recommended dose of isoflavone or Katu Leaf. 
5 CONCLUSIONS 
The current study demonstrates the eﬀect of 
Sauropus androgynus, or Katu Leaf, 15 and 
30mg/kgBW on menopausal mice uterus and their 
proliferative eﬀect, which increased the uterine 
weight. 
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